Morgan Stanley Upgrade Powers Mylan Stock Rebound

MYL is coming off its worst week since August 2017

Managing Editor
Mar 6, 2019 at 9:58 AM
facebook twitter linkedin

Mylan NV (NASDAQ:MYL) is up 1.3% to trade at $27.75, after Morgan Stanley upgraded the EpiPen maker to "overweight" from "equal weight," while trimming its price target to $35 from $39. The brokerage firm said the stock is trading nearly "historical valuation lows," and is running at a discount to its sector peers. 

This follows last week's 12.2% drop, which was Mylan stock's worst week since August 2017. A fourth-quarter earnings miss prompted a flurry of bear notes, and MYL slipped to a six-year low of $26 on Feb. 27. Today's upside takes the shares back above their year-to-date breakeven point, though the 10-day moving average is perched overhead.

Morgan Stanley's upgrade today is indicative of the general analyst sentiment. At last night's close, nine of the 15 brokerages covering MYL rated it a "buy" or better, with zero "sells" on the books. What's more, the security's consensus 12-month price target of $36.79 is a 34% premium to last night's close at $27.39.

In the wake of Mylan's earnings report last week, short-term volatility expectations have imploded on the stock. At last check, the equity's Schaeffer's Volatility Index (SVI) of 31% ranks in the 15th annual percentile.


Minimize Risk While Maximizing Profits

There is no options strategy like this one, which consistently minimizes risk while maintaining maximum profits. Perfect for traders looking for ways to control risk, reduce losses, and increase the likelihood of success when trading calls and puts. The Schaeffer’s team has over 41 years of options trading success targeting +100% gains on every trade. Rest assured your losses are effectively limited to your initial cost at the time of making your move! Don't waste another second... join us right now before the next trade is released! 



Special Offers from Schaeffer's Trading Partners